<DOC>
	<DOCNO>NCT00137033</DOCNO>
	<brief_summary>The aim current study replicate COXA-0508-258 study multicenter , US setting , use low dose ASA . It expect study confirm result 258 study show incidence UGI ulcer celecoxib significantly less traditional NSAIDs incidence UGI ulcer celecoxib increase addition ASA , still low traditional NSAIDs plus/minus ASA . This 7-day study design compare incidence gastroduodenal ulcer associate celecoxib 200 mg QD low dose aspirin 81 mg QD naproxen 500 mg BID plus low dose aspirin 81 mg QD healthy adult ( 50-75 year age ) .</brief_summary>
	<brief_title>Celebrex Low Dose ASA Study Examining Incidence Gastroduodenal Ulcers Healthy Population</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>A healthy adult 50 75 year age inclusive : normal clinical laboratory test result Screening Visit , abnormal , clinically significant Investigator 's opinion . A gastric , pyloric channel duodenal ulcer ( defined break mucosa least 3 mm diameter unequivocal depth ) 5 erosion stomach duodenum ( UGI endoscopic score great less ) baseline UGI endoscopy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>